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1. Introduction 
1.1 The definition of MSCs 
Bone marrow (BM) was the first tissue described as a source of plastic-adherent, fibroblast-
like cells that develops colony-forming unit fibroblastic (CFU-F) when seeded in tissue 
culture plates (Friedenstein et al., 1982; 1987). These cells, originally designated stromal 
cells, elicited much attention, and the main goal of thousands of studies conducted using 
these cells was to find an ultimate pure cell population that could be further utilized for 
regenerative purposes. In these studies, cells were isolated using several methods and were 
given names such as mesenchymal stem cells (MSCs), mesenchymal progenitors, stromal 
stem cells, among others. Lately, a committee of the International Society for Cytotherapy 
suggested the name “multipotent mesenchymal stromal cells” (Dominici et al., 2006). 
However, most scientists have been referring to them simply as “MSCs”. 
The precise definition of these cells remains a matter of debate. Nevertheless, to date MSCs 
are widely defined as a plastic-adherent cell population that, under closely controlled 
conditions, can be directed to differentiate in vitro into cells of osteogenic, chondrogenic, 
adipogenic, myogenic, tenogenic, or hematopoietic-supportive stromal lineages (Pittenger et 
al., 1999; Javazon et al., 2004; Alonso et al., 2008; Prockop, 2009) (Fig. 1). 
As part of their stem cell nature, MSCs proliferate and give rise to daughter cells that have 
the same pattern of gene expression and phenotype and, therefore, maintain the “stemness” 
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of the original cells. Self-renewal and differentiation potential are two criteria that define 
MSCs as real stem cells; however, these characteristics have only been proved after in vitro 
manipulation, in bulk and at single-cell level, and there is no clear description of the 
characteristics displayed by unmanipulated MSCs in vivo (Lee et al., 2010). 
 
 
Fig. 1. Source of MSCs and multipotent differentiation capacity. MSCs can be isolated from 
bone marrow, deciduous teeth, fat, hair follicles, peripheral blood, periodontal ligament, 
trabecular bone, scalp subcutaneous tissue, and skeletal muscle in adult tissues, and from 
bone marrow, liver, lung, placenta, spleen and umbilical cord in fetal tissues. MSCs can 
generate multiple mesoderm-type cell lineages, such as osteocytes, chondrocytes, 
adipocytes, myocytes, tenocytes, and stromal cells 
In contrast to other stem cells such as hematopoietic stem cells (HCSs), which are identified 
by the expression of the CD34 surface marker, MSCs lack a unique marker. The CD105 
surface antigen (endoglin) has been recently used to isolate human MSCs (hMSCs) from BM 
and such an approach enabled the characterization of freshly isolated hMSCs before culture. 
A distinct expression of certain surface antigens such as CD31 and CD45 was demonstrated 
in freshly isolated hMSCs and the expression of these molecules was lower in culture-
expanded hMSCs (Aslan et al., 2006). These data suggest, again, the alterations that hMSCs 
may undergo during culture (Boquest et al., 2005). 
In several studies, cultured MSCs have been characterized either by using cell surface 
antigens and/or by examining the cells’ differentiation potential. Lately, the Mesenchymal 
and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposed 
minimal criteria to define human MSCs: (1) MSCs must be plastic-adherent when 
maintained in standard culture conditions and form CFU-Fs in primary cultures, (2) MSCs 
must express CD73, CD90, CD105, and lack expression of CD11b, CD14, CD19, CD34, CD45, 
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CD79alpha, and HLA-DR surface molecules, and (3) MSCs must differentiate to osteoblasts, 
adipocytes, and chondroblasts in vitro (Dominici et al., 2006; Claros et al., 2008). 
1.2 The stem cell nature of MSCs 
Stem cells are defined by their ability to self-renew and by their potential to undergo 
differentiation into functional cells under the right conditions. The ongoing public 
discussion regarding whether MSCs are strictly stem cells requires a revision of the 
definition of stem cells, as MSCs apply to a wide cluster of non-hematopoietic stem-like cells 
isolated from mesenchymal tissues such as BM, adipose, amniotic fluid, and blood vessels. 
The central question would be whether they might be differentiated into cells of other than a 
mesenchymal nature. Researchers have reported that MSCs from BM and other tissues can 
be differentiated into epithelial, endothelial, and neural cells (Spees et al., 2003; Greco & 
Rameshwar, 2007; Yue et al., 2008). As stated above, there is a consensus on specific MSC 
markers, but a unique marker of “stemness” and multipotentiality has not yet been defined, 
since culture-expanded MSCs may lose some of these markers and acquire others, which are 
non-specific, but cells retain their multipotentiality (Jones & McGonable, 2008). The 
molecular signature and in vivo distribution status of MSCs remain unknown and, as such, 
subject to investigation, even though ex vivo-expanded MSCs have been widely used in 
numerous studies (Prockop, 2007; Kubo et al., 2009; Pricola et al., 2009). 
In local models, direct injection of hMSCs into the brain tissue of rats resulted in the cells’ 
long-term engraftment and subsequent migration along pathways similar to those used by 
neural stem cells (Azizi et al., 1998). The results of these studies demonstrate the 
multilineage differentitation potential of BM-derived adult MSCs and aid in defining them 
as suitable candidates for the regeneration of several mesenchymal tissues. These data 
suggest that stem cells require a specific tissue environment to develop their intrinsic 
potency (Weissman, 2000). A stem cell niche is defined as a complex, multifactorial local 
microenvironment required for the maintenance of the stem cell biology. The stem cell niche 
consists of stem cells, non-stem cells, an extracellular matrix (ECM) and molecular signals. 
Inside the niche, the stem cell can divide asymmetrically giving rise to both new stem cells 
and proliferating progenitor cells. These proliferating cells give rise to a cell population that 
undergoes differentiation (Becerra et al., 2011). Recent scientific advances have lead to a 
substantial increase in the amount of information regarding stem cell niche data. Some of 
the best-characterized stem cell niche models are Drosophila germarium or testis, vertebrate 
hair follicle, intestinal crypts, BM, and brain subventricular/subgranular zones (Fuchs et al., 
2004; Mitsiadis et al., 2007). In vitro culture conditions of single stem cells form intestinal 
crypts can give rise to organoids which may behave as self-organizing structures in the 
absence of other non-epithelial cellular niche components (Sato et al., 2009). 
1.3 MSCs and tissue engineering 
The chronic shortage of donor organs and tissues for donor organs and tissues for 
transplantation has provided the impetus for intense research in the field of tissue 
engineering (TE). Unlike pharmacology and physiotherapies they are mainly palliative, TE 
and cellular therapy seek to augment, replace, or reconstruct damage of diseased tissues 
(Chai & Leong, 2007). Tissue engineering is an emerging field that offers outstanding 
opportunities for regenerative medicine. The most common concept underlying TE is to 
combine a scaffold or matrix, living cells and/or biologically active molecules to form a “TE 
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construct” to promote the repair and regeneration of tissues. The scaffold supports cell 
colonization, migration, growth and differentiation, and often guides the development of 
the required tissue or acts as a drug delivering vehicle. Hence, TE can be defined as a 
discipline that seeks to create or to induce the formation of a specific tissue in a specific 
location through the selection and manipulation of cells, scaffolds, biologic stimuli 
(Muschler & Midura, 2002), and vascular support (angiogenesis and/or vasculogenesis), on 
which the TE paradigm is based on (Fig. 2). 
 
 
Fig. 2. Graphical illustrations showing the principles underlying tissue engineering. From the 
same authors, published by Cellular and Molecular Biology, vol. 54 (1), 40-51. Copyright 2008 
C.M.B. Edition 
The right knowledge of these interactions will create exciting new opportunities that might 
be useful in a broad array of clinical applications. As a logic consequence, today, a great 
number of multi-disciplinary groups with different backgrounds (Fig. 3) focus on various 
problems associated with TE, including cell isolation, characterization, and manipulation of 
cell proliferation/differentiation for stem cell therapy, design and elaboration of appropriate 
biomaterials as well as for development of bioreactors to enlarge tissue/organ engineering 
as a strategy to be applied in regenerative medicine. 
MSCs have recently received much attention for their therapeutic potential in regenerative 
medicine, due to their capacity to secrete soluble factors that have beneficial effects (Caplan 
& Dennis, 2006; Cuenca-López et al., 2008; Caplan, 2009). Several studies have demonstrated 
that these MSC trophic factors may enhance regeneration ability of injured tissues, inhibit 
apoptosis, limit pathologic fibrotic remodelling, stimulate proliferation and differentiation 
of endogenous stem-like progenitors, decrease inflammatory oxidative stress and modulate 
immune reactions (Meirelles et al., 2009; Lee, 2010; Rodrigues et al., 2010). 
www.intechopen.com




Fig. 3. Graphical illustration showing the multidisciplinary and complexity of interactions 
within the context of regenerative medicine. From the same authors, published by Cellular and 
Molecular Biology, vol. 54 (1), 40-51. Copyright 2008 C.M.B. Edition 
Moreover, it has been described that growth factors (GFs) can act by an autocrine, paracrine, 
endocrine, juxtacrine, ECM mediated or intracrine process (Fig. 4) (Nimni, 1997). Autocrine 
action is the secretion of GFs for which the cell possesses receptors (1). Some experiments 
have suggested that this interaction may even occur within the cell, a process called 
intracrine interaction (6). Paracrine action is defined as the release of soluble GFs which 
diffuse into the extracellular space and act upon adjacent or closely located cells (2). In the 
case of endocrine action, GFs are carried in the bloodstream and may act on distant sites 
much like a hormone (3). Juxtacrine stimulation is when one cell has surface bound GFs 
which interact with an adjacent cell containing receptors for the GF (4). Furthermore, some 
ECM molecules can bind GFs, modulating their activities and regulating how they interact 
with cells (5). 
Protein chain reaction, flow cytometry, enzyme-linked immunosorbent assay and Western 
blotting have shown that the secretion of MSCs include many major GF families and multitude 
of chemokine, including transforming growth factor beta-1 (TGF-β1), fibroblast growth factor 
(FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF), brain-derived neurotrophic 
factor (BDNF), nerve growth factor beta (NGF-β), Wnts, interleukin-1 (IL-1), IL-1β, IL-3, IL-6, 
IL-7, IL-11,  among others (Gnecchi et al., 2008; Caplan, 2009; Zisa et al., 2009). 
TGF-β1 is a multifunctional GF with a broad range of biological activities in various cell 
types in many different tissues. In general, TGF-β1 is known to influence cells from the 
chondro- and osteogenic lineage, promoting initial stages of mesenchymal condensation, 
regulating cell proliferation and cell differentiation, and stimulating production of ECM 
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(Andrades et al., 2003; van der Kraan et al., 2009; Janssens et al., 2005). Other of the trophic 
benefits produced by TGF-β1 is the immunomodulatory effect. Several authors have 
reported that MSCs suppress natural killer (NK) cell proliferation, alloreactive T-
lymphocyte proliferation and activation, cytokine production, and cytotoxicity against 
HLA-class 1 expressing targets via TGF-β1 and prostaglandin E2 secretion (Groh et al., 2005; 









Fig. 4. Chemical signaling mechanisms of growth factors. GFs (triangles) produced by the 
cells can act within itself or in adjacent or remote cells to modulate their activities by 
reacting with specific receptors. (1) Autocrine; (2) paracrine; (3) endocrine; (4) juxtacrine; (5) 
extracellular matrix mediated; (6) intracrine. Modified from Nimni ME. Polypeptide growth 
factors: targeted delivery systems. Biomaterials. 1997; 18(18):1201-1225 
FGFs are a family of GFs that act in an autocrine and paracrine way as a mitogen on many 
cell types (Chiou et al., 2006; Makino et al., 2010). They also regulate events in normal 
embryonic development, angiogenesis, wound repair, and cell differentiation. FGFs are 
involved in endothelial cell proliferation and the physical organization of endothelial cells 
into tube-like structures. They thus promote angiogenesis, the growth of new blood vessels 
from the pre-existing vasculature (Cao et al., 2003; Behr et al., 2010). Moreover, FGFs are 
important players in wound repair, stimulating the proliferation of fibroblasts that give rise 
to granulation tissue, which fills up a wound cavity early in the wound healing process 
(Schmid et al., 2009). Respect to cell differentiation, it is known that FGFs not only maintain 
MSC proliferation, they also retain osteogenic, adipogenic and chondrogenic differentiation 
potentials throughout many mitotic divisions (Tsutsumi et al., 2001; Kawazoe et al., 2008; 
Rodrigues et al., 2010).  
The anti-fibrotic effects of MSCs have been demonstrated in different animal models, but the 
molecular mechanisms are not yet fully understood. Recently, HGF has been shown to be 
involved in the prevention of fibrosis (Li et al., 2009). The results reveal that, in a situation of 
tissue injury, MSCs become proliferative and secrete HGF, which in turn mediates anti-
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fibrotic and immunomodulatory effects. Additionally, the secretion of HGF and IGF-I is 
essential for activation of cardiac stem cells, which may contribute to endogenous repair 
mechanisms (Linke et al., 2005). On the other hand, IGFs play an important role in stem cell 
maintenance within the niche (Bendall et al., 2007), and bone metabolism. During osteogenesis, 
bone cells secrete amounts of IGFs that are stored at the highest concentration of all GFs in the 
bone matrix (Wang et al., 2011). Principally, IGFs have an anti-apoptotic effect on 
(pre)osteoblast and enhance bone matrix synthesis (Meinel et al., 2003; Niu & Rosen, 2005). 
PDGF is considered one of the key regulators of general tissue repair. The main functions of 
PDGF are to stimulate cell replication of healing capable stem cells, as well as proliferation 
of endothelial cells. This will cause budding of new capillaries into the wound 
(angiogenesis), a fundamental part of all wound healing. In addition, PDGF also seems to 
promote the migration of perivascular healing capable cells into a wound and to modulate 
the effects of other GFs (Hollinger et al., 2008). 
VEGF is best known for inducing angiogenesis (Gerstenfeld et al., 2003). Further, VEGF 
induce vascular changes: increased vascular support network and permeabilization of 
capillaries (Neufeld et al., 1999; Hansen-Algenstaedt et al., 2006), which could be responsible 
for the stimulation of the recruitment of MSCs (Fiedler et al., 2005). In addition, VEGF 
secretion is also increased during MSC osteogenesis (Wang et al., 2010), thus accounting for 
the infiltration of blood vessels during bone development (Shum et al., 2003).While VEGF 
has been reported to decrease the synthesis of osteocalcin (a marker of osteoblast 
maturation) in osteogenic MSCs (Villars et al., 2000), it has also been observed to increase 
mineralization (Mayer et al., 2005) and to be regulated by proteins involved in osteoblast 
differentiation (Deckers et al., 2000), suggesting that it usually acts as and enhancer of both 
angiogenesis and osteogenesis. 
The neuroprotective effects of MSCs are principally attributed to production of neurotrophic 
factors, such as BDNF and NGF-β, that support neuronal cell survival, induce endogenous 
cell proliferation and promote nerve fiber regeneration at sites of injury (Li et al., 2002; 
Mahmood et al., 2004; Alexanian et al., 2010). Additionally, MSCs also express various 
neuro-regulatory proteins, adhesion molecules and receptors that likely contribute to the 
MSC-induced effects on neuronal cell survival and neurite formation (Crigler et al., 2006).  
Another family of proteins critical in MSC biology is the Wnt family of signalling molecules 
(Ling et al., 2009). Wnts are highly conserved proteins that are essential to limb development 
and musculoskeletal morphogenesis in vertebrates (Yang, 2003). At least Wnts 2, 4, 5a, 11 
and 16 are expressed by MSCs along with several Wnt receptors (Frizzleds 2-6) (Etheridge et 
al., 2004). Wnts are very active in determining MSC patterns of proliferation and 
differentiation (Boland et al., 2004; Baksh & Tuan, 2007), and they also play a role in cell 
adhesion and migration through their indirect interactions with the cadherin pathway. 
Therefore, MSCs themselves secrete a large number of regulatory proteins. In vivo, these 
signals work together to regulate the regenerative abilities of MSCs. By learning more about 
the mechanisms of action and interactions of each member of this microenvironment, it will 
be possible to develop the full potential of MSCs for future therapeutic applications. 
2. Skeletal tissue regeneration by MSCs 
2.1 Therapy for bone fractures and arthrodesis 
The treatment aim of bone fractures and of many orthopaedic deformities is the fusion 
between two or more bone ends or bone structures. Therapy for diaphyseal, metaphyseal or 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
114 
paraarticular fractures of long or short bones, either simple or complex, is always addressed 
to achieve permanent solid bone continuity between fractured bone fragments. The same 
comes true for orthopaedic corrections such as bone osteotomies, scoliosis or whatever 
situation where a bone discontinuity, either traumatic or therapeutic mediated, exists 
(Guerado, 2005; Guerado et al., 2005). Nowadays surgical treatment of these conditions is 
the choice for both young and old patients, as conservative treatment requires prolonged 
neighbor joints rest which results in articular stiffness and unacceptable deformities. 
Further, in many instances, non-surgical treatment will be unsuccessful in dealing with 
many low or high energy fractures, and also with orthopaedic corrections as non-union or 
malunion will occur. 
Current surgical treatment of fractures or orthopaedic deformities aimed to promote 
osteogenesis for bony fusion is still far away from being undoubtedly successful. Surgical 
site infection, implant failure, and many other complications will facilitate failure of 
achieving the main aim of surgical treatment. In many instances, even carrying out 
appropriately surgical technique, failure of what had been planned will be the final result. 
Although many techniques have been developed for non union treatment, complexity of 
them is, as far as biomechanics and biology are concerned, very difficult for accomplishing a 
successful outcome (Guerado, 2005; Guerado et al., 2005). Nonetheless, diaphyseal non-
unions and even paraarticular ones, although in some cases present difficult challenges to 
bony union, can be managed, at least, under favorable biomechanical situations; further, its 
biology can be managed with autograft. Conversely, since in spinal fusion the size of any 
vertebra and the distance to each other make the biomechanical and biological situation 
very difficult for addressing a successful treatment of fusion or non-union, current and 
forthcoming new “biological” therapies have important perspectives. In relation to bone 
therapy, spinal fusion is currently the most significant surgical technique expecting for 
progress in biological treatments. 
Surgical technique of spinal arthrodesis combines a hardware system for mechanical 
stabilization and a biological substance for bone formation enhancement. Both surgical steps 
have the aim of creating an optimal biomechanical situation together with a biological 
environment which promotes definite spinal bony fusion (Guerado, 2005; Guerado et al., 
2005). 
2.1.1 Biomechanics 
Biomechanics is indeed a very important issue in spinal surgery. As a general concept, 
spinal arthrodesis is just the treatment of multiple foci of fractures once neat decortication of 
host bone has been carried-out; consequently, correct application of any of the four main 
principles of osteosynthesis (compression, neutralization, buttressing, and tension band, 
together with accessory bridging) play a major role depending on the sort and position of 
graft used; further, not only biology but also biomechanical features of host and donor 
bones are decisive. Using the same graft, either cortical or cancellous, different placements 
may need different nature of osteosynthesis, and may make the own graft behaves in 
different ways. Therefore, only when correct stabilization has been performed, as in any 
fracture treatment, biology behaves in the wished way. Likewise provided biomechanics is 
correct, the same graft behaves in different ways depending on the biomechanical forces 
acting on it (Guerado et al., 2005).  So far, there has been a long list of bone graft substitutes, 
and strategies for bone promotion (Hecht et al., 1999; Bostrom & Seigerman, 2005; Huang et 
al., 2006; Ma et al., 2007; Thalgott et al., 2009). However only cells synthesize osteoid, and 
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none of the nowadays known bone substitutes, apart from cells transplantation, are real 
“bone substitutes”, since they do not have osteoprogenitor cells. 
2.1.2 Biology 
Grafting enhances bone fusion, and that results in permanent stability. Otherwise hardware 
fails with time. The three main properties a therapy for optimum fusion enhacement must 
have are osteogenesis, osteoconduction, and osteoinduction, together with avoidance of 
histoincompatibility, and, in the clinical setting, as said above, a favorable biomechanical 
situation (Boatright & Boden, 2002). Osteogenesis consists basically on cells differentiation 
into osteogenic linage, being bone cells the only agent with osteogenetic power. 
Osteoinduction is also very important; as mentioned before, molecules commonly called 
GFs induce MSCs to amplification (increase of cell population in number) and subsequently 
to differentiation into osteoprogenitor cells, specially the TGFs superfamily which also 
includes the well-known BMPs (Li et al., 2002). Osteoconduction is also the complement to 
osteogenesis and osteoinduction; a tridimensional scaffold structure of bone or bone 
substitute is an indispensable scaffolding for cell population growth. An osteoconductive 
microstructure of 200-400 microns is nowadays very easy to be manufactured. However 
osteoinductive GFs doses to be added to it are unknown; further osteogenetic properties of 
“bone substitutes” are lacking for osteoconductive materials, as osteogenesis is an exclusive 
property of mature osteoprogenitor cells.  
Since bone synthesis is exclusively made by bone cells, a large population of osteoprogenitor 
cells is necessary for successful fracture or spinal fusion. The larger the area to be fused the 
more number of osteoprogenitor cells are needed. Because MSCs population is very scarce 
in elderly people, this age group has a higher risk for non-union (Caplan, 1991). Nowadays 
it is known that differentiated cells do not reproduce themselves, being undifferentiated 
cells, particularly MSCs, responsible for cell amplification and subsequent differentiation 
into osteogenic linage; moreover mature osteoblasts can recapitulate back to former less 
differentiated MSCs in order to achieve amplification for increasing the final population of 
differentiated osteoblasts (McCulloch & Till, 2005; Daley & Scadden, 2008; Jones & Wagers, 
2008; Kuang & Rudnicki, 2008; Morrison & Sprading, 2008). During the entire process, the 
new-forming blood vessels that grow inside the callus act as a source of new MSCs; in fact, 
recent publications have given strong evidences of a perivascular origin for the MSCs 
(Crisan et al., 2008; Da Silva Meirelles et al., 2008; Koob et al., 2010); therefore neat 
decortication of host bone until bleeding, becomes of overwhelming importance. On the 
other hand fracture focus stability prevents new vessels and incipient callus from breakage. 
Currently, the combination of biomechanical stabilization ensuring appropriate environment 
for bone growth, osteoprogenitor bone cells for osteoid synthesis, vascularization of fusion site 
for cells and metabolite transport, signaling molecules (TGFs, particularly BMPs) to encourage 
cells to amplification and differentiation, and scaffold for tridimensional cells growth has 
been denominated the “diamond concept” (Giannoudis et al., 2007; 2008), as to the ideal 
situation for fusion to take place. Hence clinical situations lacking of any of these variables 
are in less than optimal condition for successful spinal fusion. This concept is indeed 
extended to any fracture of the skeleton or joint arthrodesis (Giannoudis et al., 2007; 2008). 
MSCs are, therefore, the centre of the osteogenesis concept, as to its amplification and 
commitment to osteoprogenitor line signifies that biomechanics is already achieved into its 
optimum, and that the appropriate environment has been created. Finding a natural source 
of viable MSCs for therapy is the star point of the diamond concept. 
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2.1.3 Autograft as a source of osteoprogenitor cells. The relation between 
biomechanics and biology in spinal surgery 
Autograft is the standard biological agent to be added in fracture or arthrodesis focus for 
bone repair enhancement (Figs. 5-8). Autograft is the appropriate biological source of cells 
whenever bone healing is required in any part of the skeleton, as its biological properties are 
considered to be optimum: autograft has a good volume effect, and also potent osteogenic, 
osteoinductive, and osteoconductive properties (Boatright & Boden, 2002; Niu et al., 2009). 
Autograft is also the standard for spinal arthrodesis as the natural source of osteoprogenitor 
cells (Fig. 6). It can be used in spinal surgery either as cancellous chips or as a tricortical 
alive implant in order to improve the immediate strength of the construct. So far, no 
allogenic or synthetic bone substitutes have achieved its osteogenicity, although careful 
autograft implantation for spinal surgery must include shortening harvesting-to-implant 
interim, because these properties diminish with time (Sandhu et al., 1999). 
Nevertheless, morbidity in donor site after autograft collection is very high, and fractures of 
iliac bone, particularly after tricortical graft has been harvested, with ensuing non-union are 
not rare, making the need for new bone substitutes (Arrington et al., 1999; Banwart et al., 
1995; Delawi et al., 2010; Epstein, 2008; Glassman et al., 2010; Slosar et al., 2007). Limited 
availability together with longer operative time are also the most important burdens in 
conventional autograft harvesting, and new less invasive aspiration techniques of cancellous 
bone from femoral and tibial metaphysis by a “Reamer Irrigator Aspirator” (RIA) 
apparently provide larger graft amounts than conventional iliac crest harvesting (Belthur et 
al., 2008; Kobbe et al., 2008a; 2008b) and with higher concentration of GFs (Porter et al., 2008; 
Schmidmaier et al., 2006); further, RIA would provoke less postoperative pain and shorter 
length of stay (Belthur et al., 2008). However studies on RIA for spinal surgery are lacking. 
 
 
Fig. 5. Cervical spine. C6-C7 interbody disc has been removed for interbody fusion by a 
tricortical autograft harvested from iliac crest 
This basic knowledge on autograft has been achieved after animal experiments, making 
clinical inference to human very uncertain. Cancellous bone graft has greater cellular 
activity than cortical, whereas cortical graft is much more dense and stronger (Day et al., 
2000). Spongy structure of cancellous bone allows osteoprogenitor cells to have better 
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vascularization, developing superior osteoconduction and osteogenesis. Anyhow although 
histological incorporation with prompt vascularization and MSCs invasion stars at the 
second day of implantation, mechanical properties of cancellous bone are compromised 
during remodelation phase, taking a few months to become structurally stronger (Pape et 
al., 2010). Cortical autograft having less biological properties than cancellous bone also 
suffers biomechanical weakening up to the 75% (19) at 6 to 24 weeks postimplantation, 
returning to normal strength some 48 weeks thereafter (Enneking et al., 1975). 
 
 
Fig. 6. Harvested tricortical autograft is prepared for implantation. Cortical layers provide 
strength for interbody compression. Cancellous bone provides biological support for 
osteogenesis enhacement and faster fusion 
 
 
Fig. 7. Tricortical graft in place 
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Fig. 8. X-ray control shows good position of graft and osteosynthesis stabilization by a plate. 
The cortical layers of the graft are positioned anteriorly facing the plate, superiorly facing 
the above vertebral body, and inferiorly facing the below vertebral body. The posterior face 
has not cortical bone 
Consequently, according to biological and biomechanical properties of autograft, spinal 
posterior artrodesis is better enhanced by cancellous autograft whereas tricortical bone 
under interbody compression is more suitable for buttressing in anterior interbody fusion, 
together with a posterior transpedicular screw system in order to provide a tension band 
principle; alternatively an interbody plating together with the interbody tricortical autograft 
provides buttressing leaving the tricortical graft healing without supporting compression; 
this last possibility may be used in any anterior surgical approach (Figs. 5-8); however in 
clinical setting it is usually preferred, by some surgeons, a 360º fusion, as surgeons feel more 
confident in case of implant failure. Eventually, during the course of thoracotomy, removed 
ribs for anterolateral thoracic or thoracolumbar approaches can substitute the use of tricortical 
grafts, suppressing the morbidity provoked by iliac crest graft harvesting. In this case the graft 
can provide limited buttressing, as ribs are not as strong as tricortical iliac crest grafts; full 
buttressing and neutralization must be supported by the hardware; anterior interbody plating 
for this purpose appears to be ideal, and ultimately posterior pedicular instrumentation either 
alone or, ideally, within a 360º fusion concept. In conclusion, failure in the correct combination 
of graft type with proper instrumentation principles will result in poorer outcome, although 
the right graft had been used or the appropriate osteosynthesis applied. 
2.1.4 Therapy with laboratory treated MSCs 
Many studies have been made during the last years in experimental MSCs application for 
therapy in animals. Nevertheless biomechanics and biology of animal used are quite 
different from humans (Heineck et al., 2010); moreover clinical situations are different from 
one patient to another. Stem cells are currently being studied for use in numerous clinical 
applications, ranging from neurodegenerative diseases to cardiac insufficiency. The use of 
MSCs in spinal surgery is also compelling, especially with the increasing age of the general 
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population. In spinal surgery, the use of MSCs is focused in intervertebral disc repair and 
regeneration and in spinal arthrodesis procedures. Although the routine use of cellular 
therapies by spine surgeons to improve outcome after a variety of surgical procedures is 
rapidly approaching with uncontrolled enthusiasm (Helm & Gazit, 2005), knowledge on its 
real effectiveness is far from being identified. 
Experimental studies on the effect of low intensity pulsed ultrasound on rabbit posterolateral 
intertransverse processes spinal fusion with MSC-derived osteogenic cells and bioceramic 
composite have shown that this combination promote clinical fusion. The mechanism was 
likely to be mediated through better osteointegration between the host bone and implanted 
materials and enhanced endochondral ossification at the fusion site (Hui et al., 2011). However 
it is known that osteogenesis in spinal rabbit is achieved just by stripping the periostium. Also 
MSCs that had been cultured with osteogenic differentiation medium may induce the 
formation of new bone in experimental posterolateral intertransverse process spinal fusion in 
rabbits. Nonetheless suitability level of osteogenic differentiation of MSCs as well as the most 
appropriate carrier for MSCs is unkown (Nakajima et al., 2007). 
New approaches and carrier have been introduced in the armamentarium for MSCs 
transplantation. It has been shown that MSCs and platelet lysate seeded in a fibrin or 
collagen scaffold can improve the new bone formation around an uncemented hip 
prosthesis stem in a sheep model. In vitro expanded MSCs suspended in platelet lysate and 
either mixed with collagen or fibrin gel as delivery vehicle inserted inside the femoral canal, 
in a press-fit femoral stem model provides higher bone-prosthesis contact (Dozza et al., 
2011). But again biology is subjected to biomechanics and human and animal hip 
biomechanics are not similar. 
MSCs transplantation will be a very important therapeutic principle, however deep 
knowledge not only on cells in cultures but also in biomechanical situations resembling 
clinical setting is needed. We know now that MSCs behave in different ways depending on 
the biomechanical situation. In fact this principle is worldwide known since more than 100 
years by any orthopaedic surgeon as Wolf’s law (Wolf, 2010). 
2.2 Cartilage regeneration 
Degenerative disease of articular cartilage (AC), generically known as osteoarthritis (OA), is 
an irreversible evolution process towards terminal articular failure. Due to its high 
prevalence on population and its socioeconomic impact, this condition is of great concern, 
and this way more resources and effort are dedicated to the research on its development. 
OA is the result of several mechanical changes and biological events that destabilize the 
balance between normal degradation and synthesis of AC, ECM and subchondral bone. 
Knowledge on OA physiopathology has improved considerably, evolving from a purely 
mechanic approach to a molecular and inflammatory view, taking into consideration that 
cartilage, synovium and subchondral bone contribute to the joint restructuring. 
Mature AC is a tissue free of blood vessels and nerves, located at the diarthrodial joints of 
the skeleton, making easier its gliding and the lubrication between the articular surfaces; it 
absorbs traumatisms and distributes load on the adjacent bone. It is made up of one ECM 
with proteoglycan, rich in type II collagen, and about only 5% of the tissue volume occupied 
by cells. These cells, the chondrocytes, are spherical, and can be found embedded inside 
lacunae filled with pericellular matrix and have no contact with the distant neighbour cells. 
Although human cartilage can reach up to 7-8 mm thickness, its supply with nutrients and 
oxygen is limited by diffusion, which is, however, facilitated by a cyclic compressive 
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loading; this provides a pumping mechanism during joint movements. There are several 
reasons that contribute to a lessened capacity of response from chondrocytes before an 
injury regarding other parenchymal cells. As it has no vascularisation, the typical provisional 
matrices made from fibrin deposits do not exist, nor the inflammatory cells afflux occurs, there 
is no delivery to the environment of cell mediators through degranulation, whereas in other 
tissues, arrival to the focus of such mediators with mitogenic, fibrogenic and phagocytosis-
inducing capacities are responsible for the repair. Although most of the actions promoted by 
the mediators of inflammation can enhance the injury magnitude (such as the proteolythic 
capacity, free radicals production, cell death or proliferation), the best guarantee for the 
restitutio ad integrum is its early delivery at the injured focus. 
Chondrocytes are well differentiated cells with a limited proliferative and migratory 
capacity. Before physiological stimuli, it synthesizes its own ECM at a very constant and 
slow rate. A macroscopic structural injury involves higher demand of matrix synthesis, 
resulting in an insufficient cell response to achieve the tissue regeneration. However, the 
regenerative capacity of the organs lies on the persistence of cell progenitors in some areas 
of the adult tissues. Mesenchymal non-differentiated cells found in the AC prove that 
cartilage, as other tissues, has the capacity to regenerate its own structure. This suggests the 
existence of a lapse of time in which the capacity or repair is complete; this period would 
possibly cover the early stages of the disease when defects are microscopic. The most 
adequate resolution of a chondral defect should involve the regeneration into a tissue 
identical to hyaline cartilage. A simple repair means the filling with a non-identical tissue, 
which should be able to seal the defective area with good adhesiveness to subchondral bone 
and total integration within the surrounding cartilage, as well as to resist the mechanic wear 
and incorporate into the natural turnover of the normal tissue. 
All this makes the AC a tissue with almost no healing capacity for intrinsic healing in most 
in vivo situations, although tissue culture demonstrates that in vitro conditions may 
reactivate a significant regenerative potential for juvenile tissue and articular chondrocytes. 
In partial cartilage defects, the subchondral plate remains intact, without access to the 
vascular system and they are not usually repaired spontaneously. On the other hand, 
defects that penetrate the full chondral thickness are generally associated to the violation of 
the subchondral plate, thus exposing the defect to the vascular system though the marrow 
area. This leads to the migration of MSCs to the damaged area, where they undergo the 
chondrogenic differentiation. Nonetheless, in many instances the repair tissue is made up of 
fibrocartilage that contains mainly collagen type I fibres, and does not meet the criteria 
precise for a functional tissue. Small defects can be repaired spontaneously with hyaline 
cartilage production, whereas larger defects will only be able to be repaired with the 
production of fibrous or fibrocartilaginous tissue, which are biomechanically and 
biochemically different from the normal hyaline cartilage. As a result, degeneration 
subsequently appears which can evolve into osteoarthritic change in some cases. 
Focal cartilage defects have been detected in up to 63% of patients undergoing arthroscopy 
of the knee and fortunately most of them remain symptomless for a long time. However, 
symptomatic lesions can result in significant pain and morbidity and a prospective clinical 
study has demonstrated that the risk of patients with a cartilage lesion to progress to 
osteoarthritis is enhanced more than fivefold. Thus, such patients require a treatment filling 
the gap between palliation and resurfacing via arthroplastia. This need as well as the 
detailed knowledge we have about the functional elements of cartilage tissue, have turned 
cartilage repair into a pioneering and very successful area of regenerative medicine. 
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2.2.1 Therapeutic interventions without active biologics 
2.2.1.1 Bone marrow stimulation 
First approaches to heal cartilage by in situ regeneration date back to 1959. Pridie technique 
was directed to BM cells recruitment to be used in cartilage defects by drilling small holes 
into the subchondral BM space underlying the damaged cartilage regions. It was improved 
later on by reducing the size of the perforations and being then called microfracture 
technique which is now a frequently performed and well studied procedure (Steadman et 
al., 1999). This technique is based on the mechanism of mesengenesis or capacity of the non-
differentiated mesenchymal cells in choosing a determined phenotype as a response to 
inducing or GFs. A non-differentiated cell from the BM can be promoted to different cell 
types such as osteoblasts, with a later maturing to osteocytes, chondroblasts and 
chondrocytes, but also to endothelial cells, mesothelial cells, fibroblasts or adipocytes. It is a 
cell signalling process of local cytokines on local cells. In order to achieve all this, the 
surgical technique is based on drilling the subchondral plate to get bleeding and a superclot 
that will become a scaffold and supply cells and proteins, starting this way the physiological 
cascade of the chondrogenic cell differentiation. Other alternative techniques of BM 
stimulation to regenerate cartilage would be abrasion chondroplasty and in case the 
articular surface remained untouched, the retrograde stimulation technique. Cartilage 
defects are repaired only with fibrous tissue or fibrocartilage when using these methods, 
probably because the number of chondroprogenitors recruited from the BM is too small to 
promote the hyaline cartilage repair and results are often followed by degeneration of the 
repair tissue. This was used as an explanation for the observations of other studies that good 
short term results may be followed by deterioration starting about 18 months after surgery. 
Clinical observations and theoretical considerations pointed towards several possible 
limitations of marrow stimulation techniques. The non-adhesive properties of the cartilage 
surface and the softness and shrinking of the superclot can lead to only partial defect filling 
and facilitate an early loss of repair tissue from the cartilage lesion. To avoid this, the 
treatment has been recently advanced into a matrix-supported technique in which the 
performed defect was stabilized in an additional way with a biomaterial. The microfractured 
lesion is covered with a collagen type I ⁄ III scaffold and it is called autologous matrix induced 
chondrogenesis (AMIC) (Kramer et al., 2006; Steinwachs et al., 2008). This technique has been 
developed to allow the treatment of larger defects by microfracturing and it is used as 
alternative treatment to autologous chondrocytes transplantation (ACT). 
2.2.1.2 Autologous osteochondral transplantation: mosaicplasty 
Autologous osteochondral mosaicplasty, sometimes known as osteoarticular transfer 
system, OATS, is an effective method for the resurfacing of osteochondral defects of the 
knee. The technique consists in transplantation of many osteocondral autologous plugs 
obtained from the periphery of the femoral condyle articular surface, which supports less 
weight and transferring them to create a durable resurfaced area in the defect (Fig. 9). The 
procedure shows some advantages regarding other repair techniques, such as the viable 
hyaline cartilage transplantation, a relatively short rehabilitation period and the possibility 
of carrying out the procedure in one only operation. 
However, the OATS limitations are the donor-site morbidity and a limited availability of 
grafts that can be obtained from the femoropatellar joint or the area adjacent to the 
intercondylar fossa. Other possible limitations are differences in bearing, thickness and 
mechanical properties between the donor’s and the receiver’s cartilages, as well as the graft 
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sinking into the surface due to the support of weight after surgery. Besides, the lack of filling 
and the possible dead space between cylindrical grafts can limit the repair quality and 
integrity. Lane et al. transplanted autologous osteochondral grafts into sheep knee joints and 
reported the lack of integration of the cartilage, which determined the persistence of gaps 
through the full thickness in all the specimens (Mishima et al., 2008). 
 
  
Fig. 9. In mosaicplasty cylindrical osteochondral plugs are harvested from nonload-bearing 
sites in the affected joint and pressed into place within the osteochondral defect, creating an 
autograft “mosaic” to fill the lesion 
2.2.1.3 Alogenic osteochondral transplantation 
Osteochondral allograft transplantation is a procedure for cartilage resurfacing which 
involves the transplantation into the defect a cadaveric graft composed of viable, intact AC 
and its underlying subchondral bone. It is a well known resource, especially for tumour 
surgery. The defect size, its location and its depth are crucial factors for the suitability of the 
donor graft. Advantages of using osteochondral allografts are the possibility if achieving a 
precise architecture of the surface, the immediate transplantation of viable hyaline cartilage 
in a one-time procedure, the possibility to repair large defects, even half-condyles and the 
donor-site lack of morbidity. Gross et al. have reported results from fresh allografts in 123 
patients with good clinical results in 95% of the patients after five years (Gross et al., 2002). 
There are different possible allografts. Fresh osteochondral allografts are generally used 
because both freezing and cryopreservation have proved to reduce the chondrocytes 
viability. Traditionally grafts have been obtained, kept in lactated Ringer’s solution at 4 °C 
and then transplanted in a week. Another alternative for allografts conservation and 
implantation is cryopreservation, which involves freezing at a controlled speed of 
specimens within a nutrients rich medium, a cryoprotector agent (glycerol or dymethil 
sulfoxide), to minimize the cells freezing and keep their viability; finally, there is the 
possibility of fresh-frozen allografts, with the advantages of lower immunogenic capacity 
and less transmission of diseases but with lower chondrocyte viability. 
2.2.1.4 Soft tissues transplantation 
Two main theories support the practicing of covering the cartilage defects with soft tissues, 
such as perichondrium or periosteum. On one hand, the defect has to be covered 
mechanically and on the other, we know about the presence of pluripotential stem cells in 
the perichondrium and the periosteum cambium layer. The different factors able to promote 
these cells differentiation into active chondrocytes still remain unknown. 
www.intechopen.com
 Skeletal Regeneration by Mesenchymal Stem Cells: What Else? 
 
123 
2.2.2 Therapeutic interventions with active biologics 
2.2.2.1 Autologous chondrocytes implant 
The clinical use of the autologous chondrocytes implant (ACI) technique was first reported 
by Brittberg et al. in 1994, following animal studies which had shown its effectiveness 
(Grande et al., 1989). In this method, chondrocytes are obtained from a biopsy taken from a 
non-weight bearing part of the patients cartilage, and are expanded in vitro, followed by the 
injection of a suspension of chondrocytes into cartilage defects, covered with autologous 
periosteal flap (Fig. 10). This technique premises are based on the capacity of adhesiveness 
of the cells to certain surfaces, they spread on them and proliferate producing their specific 
ECM. Although clinical results of the original ACI looked promising (Minas, 2001; Peterson 
et al., 2000), this procedure has some potential disadvantages, such as leakage of 
transplanted cells, invasive surgical method, hypertrophy of periosteum (Haddo et al., 2005; 
Kreuz et al., 2009) and loss of chondrogenic phenotype of expanded chondrocytes in 
monolayer culture (Benya & Shaffer, 1982). Second generation ACI, named membrane 
autologous chondrocyte implantation (MACI), has a similar procedure, but a collagen type I 
and III membrane instead of periosteum. This technique was introduced to improve the ACI 
problems, and biomaterials such as collagen type I gel (Ochi et al., 2002), hyaluronan-based 
scaffold (Manfredini et al., 2007) and collagen type I/III membrane (Bartlett et al., 2005) 
were applied to secure cells in the defect area, to restore chondrogenic phenotype by way of 
three dimensional cultures (Gigante et al., 2007]) and to replace the periosteum as defect 
coverage. This is the way MACI technique is created a posteriori, by implanting autologous 
chondrocytes in three dimensional matrices of collagen types I and III, or hyaluronic acid. 
 
 
Fig. 10. In autologous chondrocytes implantation (ACI) a chondral biopsy is taken from a 
donor site at the time of clinical examination to be treated with enzymes in the laboratory to 
obtain chondrocytes cultures that are re-injected under the periosteal flap 
At present, only two prospective studies comparing the original and second generation ACI 
are available (Bartlett et al., 2005; Manfredini et al., 2007) and both studies show no 
significant differences in the short term clinical results. As for the first generation ACI, the 
newly regenerated cartilage often consists of fibrous tissue (Horas et al., 2003; Tins et al., 
2005), possibly due to the limited number of chondrocytes and their low proliferation 
potential. Bone overgrowth that causes thinning of the regenerated cartilage and the 
violation of the tidemark are also of concern. Moreover, this method still sacrifices healthy 
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cartilage. Thus, these aspects limit ACI in the treatment of large defects and may increase 
the long-term risk of osteoarthritis development. 
2.2.2.2 Mesenchymal stem cells therapy 
TE based on cell and genetic therapy offers some of the most promising strategies of tissue 
repair, including AC repair. It is the science able to create alive tissue to replace, repair or 
strengthen ill tissue. Thus, the term tissue engineering refers to a wide variety of techniques. 
Regardless of the used technique, it needs four components (Fig. 2): a growth inducing 
stimulus (GF), cells that may respond to such influences, a scaffold that might provide a 
support for the tissue generation, and vascular support (angiogenesis and/or 
vasculogenesis). This approach involves the use of different cell types acting as 
chondroprogenitor cells and/or vehicles for supply of genes that synthesize therapeutic 
proteins. MSCs provide a new potential for cartilage regeneration, as their differentiation to 
several lineages can be induced, in this case into chondrocytes. Destiny of these cells within 
tissues is determined by specific cell–to-cell and cell–to-matrix interactions and is controlled 
by extracellular signalling molecules and their respective receptors and by events that 
control genetic transcription in a cell-specific way. It has been shown that several 
differentiation factors are required, such as the BMPs, the FGF and Wnt molecules, although 
they are not specific for chondrogenesis (Jorgensen et al., 2004). These factors promote the 
formation of cartilage as well as of bone in vivo (Noel et al., 2004), and the precise molecular 
pathways that rule each specific lineage are being researched.  
Beside the characteristics of MSCs exposed before, these cells have self-renewal potential as 
well as multilineage differentiation potential, including chondrogenesis (Johnstone et al., 
1998; Pittenger et al., 1999; Prockop 1997; Sacchetti et al., 2007). MSCs chondrogenesis was 
first reported by Ashton et al. (1980) and the first ones to describe a defined medium for in 
vitro chondrogenesis of MSCs were Johnstone et al. (1998), who used micromass culture 
with TGF-β and dexamethasone. Sekiya et al. (2001, 2005) reported that addition to bone 
BMPs enhanced chondrogenesis under the conditions employed by Johnstone et al. (1998). 
Nowadays, the micromass culture is widely used to evaluate chondrogenic potential of 
MSCs in vitro. However, this in vitro chondrogenesis does not mimic cartilage formation 
during development. During micromass culture, MSCs increase expressions of both collagen 
type II (chondrocytes marker) and X (hypertrophic chondrocytes marker) (Barry et al., 2001; 
Ichinose et al., 2005). Other cytokines such as IGF (Pei et al., 2008) and parathyroid hormone-
related peptide (PTHrP) had been tried for better differentiation cocktails, but it is still difficult 
to obtain in vitro MSC-based cartilage formation comparative to native cartilage tissue. 
Although BM is considered an acceptable source of MSCs some comparative studies show 
that MSCs from BM have more chondrogenic potential in vitro than those from the adipose 
tissue (Colter et al. 2001; Huang et al. 2005; Liu et al. 2007; 53, 54). Sakaguchi et al. (47) 
harvested human BM, synovium, periosteum, muscle and adipose tissue and isolated and 
expanded MSCs in a similar condition. They demonstrated that MSCs derived from 
synovium had higher chondrogenic potential than those from other mesenchymal tissues. 
Yoshimura et al. (71) also demonstrated in a similar way higher chondrogenic 
differentiation potential of MSCs from synovium in rats. Park et al. (72) showed that MSCs 
from BM and periosteum are superior to cells isolated from fat with respect to forming 
hyaline cartilaginous tissue when transplanted into cartilage defects in rats.  
To start any regeneration based on MSC activity, first the cells have to be recruited to the 
damage site. Second step is adhesion to local matrix, followed by activation and extensive 
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proliferation to provide the necessary number of chondroprogenitor cells to build up new 
tissue. Finally, it is required to switch from expansion to chondrogenic matrix production 
via chondrogenesis induction, to build up the shock absorbance and gliding characteristics 
for a proper tissue function. Seamless integration with neighbouring cartilage and bone 
tissues depends on successful crosstalk between new and old tissues. For durable cartilage 
repair, the tissue eventually needs to regenerate a tidemark, get adapted to mechanical 
loading and build up a balanced tissue homeostasis. 
Cell migration is a requisite for development from conception to adulthood and plays a 
major role in regeneration of all tissues. A number of studies demonstrated that 
chondrocytes migrate under the action of different stimuli, on or within planar and 3D 
matrices. Attracting factors include BMPs (Frenkel et al., 1996), hepatocyte growth factor 
(HGF) (Takebayashi et al., 1995), IGF-1 (Chang et al., 2003), TGF-β (Chang et al., 2003), 
PDGF (Fujita et al., 2004), FGF (Hidaka et al., 2006), fibronectin, fibrin and collagen type I 
(Maniwa et al., 2001). However, results remain contradictory for some of these factors, as 
testing of human chondrocytes revealed no effects for BMP-2, BMP-4, BMP-7, IGF and TGF-
β in other studies (Mishima &, Lotz, 2008), being IGF-1, PDGF (Fiedler et al., 2004; Ozaki et 
al., 2007; Ponte et al., 2007) and VEGF the ones that induced higher response (Mishima & 
Lotz, 2008). Effects of GFs vary in vitro and in vivo, regarding animal species and specimens’ 
age, among other aspects. But it is generally accepted that GFs stimulate the synthesis of the 
cartilage ECM components, they inhibit proteases and activate their inhibition systems. 
Thus, TGF-β illustrates perfectly the complex as well as paradoxical nature of the action of 
the GFs, which on one hand can increase or decrease the expression and activity of some 
metalloproteinases (MMP) produced by articular chondrocytes, increasing MMP-9 and 
reducing MMP-2. Another anabolic factor for chondrocytes is IGF-I, which can keep 
chondrocytes phenotype in vitro, stimulate intensely the synthesis of proteoglycans and type 
II collagen, as well as block the harmful effects induced by IL1 on the proteoglycans 
degradation. On the other hand, both IGF-1 and TGF-β stimulate the expression on the cell 
surface of the subunits of integrins a3- and a5-, as well as adhesion of chondrocytes to 
fibronectin and collagen type II, being integrins, accepted as the main receptors, the 
molecules used by the cells (chondrocytes, in cartilaginous tissue case) to adhere to ECM. A 
new GFs family has been reported, Wnt, with a major role in chondrocyte differentiation. 
Wnt family members are important regulators of several development processes, including 
skeletogenesis. After the binding of Wnt to the Frizzled receptors family and the LRP5/6 co-
receptors family, the canonical Wnt pathway will stabilize the β-catenin, which translocates 
to the nucleus and interacts with members of the TCF/LEF (β-catenin-T-cell 
factor/lymphoid enhancer factor) families to activate target genes. Whereas inactivation of 
β-catenin causes ectopic formation of chondrocytes at the expense of osteoblasts formation, 
the canonical Wnt pathway leads to enhanced ossification and suppression of chondrocytes 
due to the transcriptional downregulation of Sox9 (Boyden et al., 2002; Guo et al., 2004). In 
fact, Church and colleagues have shown that Wnt4 blocks the chondrogenesis start and 
accelerates the terminal chondrocyte differentiation in vitro, while Wnt5a and Wnt5b 
promote early chondrogenesis and inhibit terminal differentiation in vivo (Church et al., 
2002). On the other hand, Wnt7 blocks chondrogenesis (Tufan et al., 2002). These studies 
illustrate that Wnt/β-catenin signalling play an essential role on MSCs by controlling 
osteoblastic and chondrocytic differentiations. 
Once the process of activation and attraction for the tissue repair has been started, we have 
just to review MSCs proliferation or expansion. Requisites for human MSCs growth are 
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different than those for other species and several factors have been identified as potent 
mitogens, taking PDGF-BB, EGF and TGF-β as the most important ones, leading jointly cell 
migration and proliferation steps. MSCs have been expanded with foetal bovine serum 
(FBS), supplemented with GF, for research as well as for clinical use; this supplementation 
with FBS has several risks such as diseases transmission or immune reactions, which 
promoted the development of research lines with  autologous human serum as substitute 
for FBS. Human platelet lysate (hPL) has been also proposed as a substitute for culture and 
expansion of MSCs, and some reports showed that there is a higher proliferation in hPL 
regarding FBS, keeping their differentiation potential including chondrogenesis. 
Finally, as one of the basic columns of the tissue repair we have to highlight the importance of 
scaffolds, because treatment with MSCs requires cells and scaffold transplantation. Importance 
of such structures is based on their ability for a fast filling of defects, their raised persistence to 
carry out repair, they also achieve an uniform distribution of cells in an enhance volume and 
also because they provide an active environment that may allow the local delivery of local 
molecules to stimulate repair (Andrades et al., 2010). Many studies have reported that using 
several scaffolds improve the new tissue quality. Such scaffolds are based mainly on 
hyaluronic acid, polylactic acid and/or polyglicolic acid, which can help to keep the cells 
inside the defect and provide a chondroinductive matrix. Natural materials, such as agarose, 
alginate, gelatine and collagen derivatives are inferior than synthetic and hybrid materials, due 
to a poor resistance to mechanical stress, so their clinical usefulness is severely limited. We 
have to take on account that MSCs chondrogenic potential is favoured by hypoxia and that it 
does not only depend on hydrostatic pressure, but also on cell density within the matrix, as 
well as on the presence of GFs. It is suggested by the obtained information that scaffolds or 
matrices allow the cell differentiation and the maintenance of a mature phenotype (Fig. 11); 
this combined with the use of stem cells, provides us promising perspectives for the 
regeneration into a functional tissue (Becerra et al., 2010; Reddi et al., 2011). 
 
 
Fig. 11. Scanning electron microscopy of natural alginate wire mesh containing chondrocytes 
From the knowledge of these biological phenomena of in situ repair, adequate conditions for 
cartilage repair based on MSCs are considered. Although some studies demonstrate that 
non-differentiated MSCs transplantation in cartilage defects, without scaffolds and not 
having been chondroinduced provided good, it has been reported that the before mentioned 
cytokines and particularly the association of TGF-β and BMPs improve the cartilage repair 
when combined with MSCs. Such stimuli could be obtained by direct administration of 
recombining GFs in the culture media or via transfer of the respective genes. Thus, the 
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possibility of considering genetic therapy as an applicable measure for the treatment of 
cartilaginous lesions arises. 
2.3 Approaches for tendon regeneration 
Tendons make part of a biomechanical chain formed by muscle, bones and tendon itself. 
Muscle contraction is converted by tendons into bone motion or viceversa; thus, tendon’s 
main function is the transmission of force. Far from being a passive element, thanks to its 
composition and structure tendon has an adaptive, dynamic behaviour to face special 
functional requirements. 
2.3.1 Tendon composition, structure and mechanical properties 
Tendon is a dense connective tissue. Having to withstand basically tensile stresses, tendons 
are bundles of fibrillar proteins aligned parallelly to the tendon’s longitudinal axis, with 
small amounts of other ECM components, specialized cells (tenocytes, fibroblasts), vessels 
and neuroreceptors. Between a 75% and a 96% of a tendon’s dry weight is constituted by 
collagen, around a 2% by elastin. These proteins are imbibed in a mucopolysaccharide gel, 
the ground substance, formed mainly by hyaluronic acid and chondroitin sulfate, 
proteoglycans (decorin) and glycoproteins (fibronectin), which may account for a 1% of the 
tendon’s dry weight (Crisp, 1972; Hooley, 1977). Collagen comes mainly as type-I collagen, 
with its characteristic hierarchical organization (Fig. 12) so important to understand the 
tendon’s overall mechanical behaviour (Kastelic et al., 1978; Kastelic & Baer, 1980; Baer et al., 
1975; Silver et al., 2003; Wang 2006): tropocollagen molecules assemble into microfibrils, 
these microfibrils into subfibrils, and several subfibrils give rise to a collagen fibril, with a 
characteristic 65 nm periodicity visible in scanning electron microscopy. Assemblies of  
 
 
Fig. 12. Type I collagen hierarchical organization in tendon. Modified from Kastelic J et al. The 
multicomposite structure of tendon. Connective Tissue Research 1978; 6:11-23 
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fibrils bound by a thin layer of connective tissue (the endotenon) form typically crimped 
planar ribbons, with a periodicity of the order of a hundred microns, visible for the optical 
microscope. Packages of these ribbons surrounded by the epitenon (a sheath of loose 
connective tissue) constitute one tendinous bundle or fascicle; several fascicles may 
constitute larger units, and a tendon may consist of several of these units surrounded, again, 
by a layer of connective tissue (paratenon). Blood and lymphatic vessels, nerves and cells 
reside in the endo-, epi- and paratenon. Elastin, as said, is much less abundant in tendon than 
collagen, and is believed to help recover the original configuration of collagen fibres after 
cessation of applied stresses thanks to its rubberlike elasticity. The ground substance is a 
highly hydrated gel that allows for the diffusion of nutrients, signals and metabolytes to and 
from the cellular component of the tendon, contributing also to its mechanical behaviour as it 
is sheared during fascicle extension, (Minns et al., 1973; Kastelic & Baer, 1980). 
 
 
Fig. 13. Mechanism of internal deformation of tendon. Modified from Wang JH. 
Mechanobiology of tendon. Journal of Biomechanics 2006; 39:1563-1582 
The crimped geometry of the parallelly aligned collagen-I fibre bundles and the properties 
of the highly crystalline collagen fibrils are the main responsibles for the tendon’s overall 
mechanical behaviour. The main feature of this behaviour is its nonlinear viscoelasticity, 
‘nonlinear’ meaning that the tendon’s stiffness increases as it is progressively stretched, and 
‘viscoelastic’ meaning that the mechanical response of the tissue to an external stimulus 
does not adjust instantaneously but lags in time, giving rise to the phenomena of stress 
relaxation and creep (Hooley et al., 1978; Monleón & Díaz, 1990). Thanks to both 
characteristics tendon is able to damp sudden stresses transmitted to muscles and to achieve 
a progressive adaptation of the whole biomechanical chain to varying mechanical stimuli. 
The origin of nonlinearity lies in the mechanism of internal deformation of tendon: the 
undulation (‘crimping’) of the collagen ribbons is not uniform, but its angles with the 
longitudinal axis of the tendon are distributed; thus, as the tendon is progressively 
deformed a varying number of ribbons first straightens out, and then become stretched 
(Kastelic & Baer, 1980; Monleón & Díaz, 1990). This gives rise to a typical nonlinear, convex 
stress-strain relationship, with an initial (‘toe’) region of low modulus extending up to some 
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2-3 % of strain, and a subsequent (‘linear’) high-modulus part, which corresponds to a state 
in which most of the tendon fascicles have lost their rest wavy crimp and are bearing load 
(Fig. 13). Physiological regime of tendons lies in the strain interval up to 5-7 %, but this 
figure may vary considerably depending on age, weight, tendon type and other factors. 
2.3.2 Cell response to mechanical stimuli 
Even though tendon is a very poorly cellularized tissue, its cells are very important during 
development and healing, and thus a consideration of their role is critical for cell therapy 
purposes. Endothelial cells and synovial cells are present in the peritendon, but specialized 
fibroblasts (tenoblasts and tenocytes) are the dominant cell type. Tendon fibroblasts align in 
rows between collagen fibre bundles, and are responsible for synthesizing the ECM proteins, 
organizing them into their characteristic structures, and  remodelling the ECM during tendon 
healing. These processes occur as a consequence of the biochemical and mechanical stimuli 
transmitted to the cells by their ECM. Tendon cells respond to mechanical forces by altering 
gene expression, protein synthesis, and cell phenotype. Mechanotransduction (the conversion 
of mechanical stimuli into biochemical signals leading to cell response) is a not entirely 
understood complex process which involves the interaction of proteins from the ECM, 
transmembrane integrins and G proteins, and cytoskeleton proteins such as actin. This 
interaction triggers signalling pathways that lead to differential gene expression and protein 
synthesis by the cells (Wang, 2006). Increased ECM protein production occurs as a 
consequence of GF release stimulated by mechanical loading (Skutek et al., 2001; Kim et al., 
2002); matrix remodelling is also influenced by mechanical stimuli, which enhance the 
secretion of matrix metalloproteinases (Archambault et al., 2002; Tsuzaki et al. 2003). Different 
mechanical loading conditions lead to varying proportions of ECM proteins produced. 
2.3.3 Lesions, standard approaches and challenges posed to cell therapy 
Weakly injured tendons tend to heal spontaneously, but the remodelled tissue usually has 
poorer mechanical properties than the original one. More extensive trauma and 
degenerative processes, tumors or congenital malformations may require different degrees 
of surgery, including transplantation. Autologous grafts are in these cases the golden 
standard, but they may result in donor site morbidity and there may be lack of sufficient 
supply; artificial prostheses have not until today stood up to the requirements to represent 
an alternative. Cell therapy and engineered tendon constructs would be of utility in these 
cases (Thorfinn et al., 2010). The pluripotency discovered in several cell types, embryonic 
and adult, opens the way to their differentiation into tenocytes and their transplantation into 
injured or defective sites. A pure cell supply strategy, however, may be appropriate to small 
defects and injuries, but does not seem to be sufficient in cases of extensive tissue loss or 
rupture; here cell supply will presumably have to be combined into an engineered tendon 
construct with biomaterials acting as supporting or guiding structures and maybe GFs 
enhancing matrix production, remodelling and neovascularization. It is a challenge for this 
strategy to identify suitable candidates for a scaffold material and architecture, for the cell 
type to be supplied, for the GFs, their concentration and their release kinetics, and, maybe, 
for a cell training strategy through convenient ex vivo stimuli in bioreactors. 
2.3.4 Tissue engineering and cell therapy of tendons 
The paradigm of the TE approach is a biodegradable scaffold seeded with cells and 
bioactive factors, such that the scaffold is progressively replaced by neotissue formed in situ, 
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hystologically and functionally normal. The scaffold must initially bear the full mechanical 
load, but this must soon be gradually transferred to the ingrowing tissue to ensure the 
mechanical stimuli on the cells necessary for them to differentiate and produce and organize 
the ECM. A part of this process may take place ex vivo, in bioreactors. In vitro and in vivo 
animal studies have been undertaken along lines aiming to understand the relative 
influence and cross-talk of all these factors: (i) scaffolds, (ii) cell types supplied, (iii) 
biochemical signals, and (iv) mechanical stimulation. 
i. Three dimensional environments for cells have proved to be necessary to achieve in vitro 
significant tendon-like matrix production (Garvin et al., 2003), and such 3D scaffolds are 
also likely to make part of any successful in vivo strategy. Synthetic materials available for 
scaffold fabrication belong to the standard families of polyesthers (polylactic and 
polyglycolic acid and their copolymers, polycaprolactone), and they have been assayed 
with different morphologies, including knitted and electrospun versions (Ouyang et al., 
2003; Guo & Spector, 2006; Thorfinn et al., 2010; Ladd et al., 2011; Jiang et al., 2011). None 
of these synthetic materials, however, possesses mechanical properties approaching 
those of natural tendon; the less so when they have a porous or microfibrilar structure. 
Moreover, the effects of their degradation process have to be taken into account, since 
they imply local acidification. This is why many researchers show preference for 
different collagen-based gels, where cells are seeded and reside as in a 3D matrix, and 
can be tested in vitro (Garvin et al., 2003; Kuo & Tuan, 2008); these gels could also serve 
as vector (transport, localization) for the supply of cells in vivo. However, these collagen 
gels are even less resistant than the synthetic polymers, and thus their utility in vivo has 
to be limited to those cases involving only limited injuries and defects, and where more 
complex regeneration and extensive reconstruction is not required. Nonetheless, 
systems based on these gels could be the solution also for these latter cases if they could 
be engineered in vitro to develop a high modulus construct which would be then 
transplanted, and this is the hope of much current work. All in all, scaffold choice, its 
composition and structure, remains an open problem for tendon TE. 
ii. The cells to be employed in tendon regeneration should be capable of producing and 
organizing into its functional structure the ECM of tendons; they may be adult or 
embryonic, differentiated or pluripotent (stem) cells, autologous or not. For obvious 
reasons, adult autologous cells seem those more probable to enter a clinical solution; 
and, since BM MSCs and adipose tissue-derived stem cells (ADSC) have been 
successfully differentiated to functional tenocyte-like cells (Altman et al., 2001; 
Hoffmann et al., 2006; Juncosa-Melvin et al., 2007; Lee et al., 2007), it is they who are 
receiving most attention. Bone MSCs, in particular, are cells likely to enter wounded 
areas, and they have demonstrated a paracrine effect on tendon fibroblasts, secreting 
factors which enhance cell migration and proliferation (Shimode et al., 2007). Significant 
results have been obtained with ADSC in vivo (de Matos Carvalho et al., 2011). 
However, the sole transplantation of MSC into tendon defects does not improve 
significantly the tendon’s microstructure, and the cells should be induced into the 
tenocytic linage by specific molecules (Araque et al., 2011). 
iii. Since a natural regeneration accompanies healing processes, an understanding of 
natural tendon healing and the cascade of signals involved in it is crucial for the design 
of cell therapy strategies. A number of GFs that play an important role during the 
inflammatory, repairing and remodelling stages of the healing process has been 
identified, the most important ones being IGF-1, PDGF, VEGF, bFGF and some of the 
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TGF-β family (Molloy et al., 2003). Specific molecules which selectively induce the 
tenocytic differentiation of MSC while supressing their osteogenic and chondrogenic 
differentiation have been identified (Hoffmann et al., 2006); they may provide a 
powerful platform for successful tendon regeneration when combined with mechanical 
stimulation within scaffolds. 
iv. Though MSC have been made to express tendon-like phenotype and produce aligned 
collagen-I, mechanical properties of the neotissue produced could not match those of 
native tendon unless the cells had been subjected to mechanical stimulation (Juncosa-
Melvin et al., 2006; Benhardt & Cosgriff-Hernández, 2009). Several types of bioreactors 
have been developed which allow to apply load uniaxially, in a static or dynamic 
(cyclical) mode, to seeded constructs (Guo & Spector, 2006; Garvin et al., 2003; 
Abousleiman et al., 2009). With their help it has been possible to check hypotheses as to 
the importance of force magnitude, strain amplitude, time frequency of loading, 
loading duration, and synergisms with GFs on the proliferation, differentiation and 
ECM production of cells. An excessive mechanical conditioning has been shown to lead 
to tendon disorders and matrix degeneration, however; thus, optimal values of those 
mechanical parameters must be determined (Wang, 2006). Generally, cyclic stress 
application has resulted in better results than static stresses as regards matrix formation 
and fibre alignment (Kuo & Tuan, 2008; Benhardt & Cosgriff-Hernández, 2009; Nguyen 
et al., 2009). 
Taking into account those concepts, we are currently investigating the potential of human 
MSCs to differentiate into functional tenocytes. This cell application is directed to heal 
tendon and ligament injuries using either biosutures (Fig. 14) or poly-l-lactic acid (PLLA) 
scaffolds microparticles (Fig. 15) that could represent adequate surfaces for MSCs adhesion, 
proliferation and differentiation to tenocytes. 
3. Conclusion 
In the last ten years we have published reports suggesting that MSCs have a promising 
potential to be utilized for regenerative medicine. For example, our laboratory has 
accumulated experience working in vitro with blood-, fat-, skeletal muscle-, BM-, and now 
synovial-derived MSCs, performing ectopic implants (in mouse and rat), preclinical trial 
with small animals (rabbit, using an osteochondral defect model), with big animals (sheep, 
using a spinal fusion model), and with a pilot clinical trial in a patient affected by 
osteomyelitis. Cells to be used for an efficient regenerative medicine should be chosen. 
Undifferentiated versus differentiated or predifferentiated cells will be the choice. A 
permanent solution will come when the new tissue built in the defect is of the same nature 
and is perfectly integrated in the whole structure in any pathology and in any age. Only in 
such as way structure and function will be fully recovered. 
When regenerative medicine started several years ago, the main goal was for the implanted 
cells to directly participate in the reconstruction of the damaged tissue. But now, after the 
reported paracrine effects in several MSCs therapies we know that MSCs, far from building 
those tissues, they exert immunomodulatory functions, secreting, in addition, several 
bioactive molecules that inhibit apoptosis and scarring at sites of injury, and stimulate 
angiogenesis and mitosis of tissue-specific progenitors (Caplan, 2009; Ito et al., 2010; Park et 
al., 2010). These actions have been found either when the implanted MSCs coming from BM 
or adipose derived in adherent cell cultures (García-Olmo et al., 2010) or when the 
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mononuclear fraction of BM was infused. We cannot predict the extent of the paracrine 
effect, immunomodulatory, or if the effective replenishment of differentiated cells can be 
assigned, in each case, to the MSCs, or whether these effects have some degree of integration 
between them. We cannot even know if all those effects can influence the surrounding tissue 
positively during regeneration, but perhaps negatively towards the pathogenesis of cancer 
and metastasis (Kuhn & Tuan, 2010). For now, we can only say that in many cases, these 
actions have a certain synergy to the purpose they claim. In the future, in might be useful to 
know the responsibility of each action in the regenerative process in order to control it 
appropriately. All this indicates the necessity to highlight again the importance of a tight 
control over the stem cell culture method in order to define the cell products for 
transplantation properly, according to the specific functional outcome sought. 
 
   
Fig. 14. Fresh collagen type I containing human MSCs embedding a resorbable polyglactic 
suture in vitro. After 30 min. of incubation at 37 ºC, the collagen gelify and cells oriented 
around and along the suture line, as we can see under a fluorescence microscope (grean: 
hMSCs transfected with the green fluorescent protein) 
 
  
Fig. 15. Scanning electron microscopy of PLLA microparticles containing human MSCs 
attached to their surfaces after 14 days in culture, and their phenotypic features by confocal 
microscopy (blue: cell nuclei, grean: actin cytoskeleton, red: collagen type I) 
www.intechopen.com
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